Mr Mrs Miss Ms Dr Other

Dr
Robert
Scanes

Patent Attorney

London Office

Chemistry

Telephone. +44(0) 207 776 5100
Email. [email protected]
Vcard

Experience

Robert specialises in patents and related IP rights in the fields of chemistry, pharmaceuticals and biotechnology.

He has broad experience in patent practice, including urgent drafting for SARS-CoV-2 antivirals during the COVID-19 pandemic, coordinating global patent portfolios for a pharmaceutical candidate in phase III clinical trials and contentious proceedings before the European Patent Office defending market exclusivity determining patents for authorised drugs. Robert also provides advice regarding freedom-to-operate and validity.

He is familiar with the differing needs of prosecuting applications in several fields, encompassing consumer goods, graphene technology and polymer chemistry.

Robert's technical experience spans the interface between chemistry and biology, working on new chemical entity, polymorphic form, dosage regimen and subsequent medical use cases.

Before joining the profession Robert discovered a new oscillating chemical reaction during his doctoral research, work that was highlighted in the journal Science. His laboratory work reflected his long-held interests in enantioselective catalysis, non-linear reaction kinetics, protocell movement, oligonucleotide modification and super-resolution microscopy. He holds a first class Master's degree in Natural Sciences from the University of Cambridge, where he was awarded scholarships and bursaries for academic performance.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
Europe

BA

BA in Natural Sciences, First Class, University of Cambridge

MSCI

Natural Sciences, First Class, University of Cambridge

POSTGRADUATE DIPLOMA OR CERTIFICATE

Intellectual Property Law, Distinction, Queen Mary University of London

OTHER

DPhil in Organic Chemistry, Thesis Title "Selection among Replicators and Protocell Chemotaxis", University of Oxford

Publications

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

View publication online

T 0295/22: Apremilast decision highlights hopes and challenges for broad second medical use claims

View publication online

T 1418/22: Acalabrutinib provides guidance on establishing inventiveness of polymorphs at the EPO

View publication online

Related News

HGF Sets the Gold Standard – Recognised for 7th Year in a Row by Financial Times

We are extremely honoured to announce that HGF has once again been ranked ‘Gold’ across all six bands in the Financial Times Special Report – Europe’s Leading Patent Law Firms …

Read article

HGF receives exceptional results in IAM Patent 1000 rankings 2025

We are proud to announce that HGF has once again achieved outstanding recognition in the IAM Patent 1000 – The World’s Leading Patent Professionals 2025. With 29 of our attorneys …

Read article

Innovation in the Energy Industry - Do You Have Freedom to Operate?

The energy transition has brought unprecedented change to the energy sector. Whilst change can bring uncertainty and challenges, it also brings opportunities. Many companies have already seized on the opportunity …

Read article

The Strawberry Patent Battle: Seeds, Speculation, and Jurisdiction

  This case, relating to infringement of a US plant patent, deals with the evidentiary burden required to show infringement of a plant patent in the US, as well as …

Read article
Event - 3rd June 2025

Salzburg Seminar: Patents, trademarks, intellectual property rights – how startups can act strategically

Young companies make many important decisions during the start-up phase. One of the most important questions is: How do I deal strategically with innovations, ideas, and brand development? Those who …

Event details

European Innovation Remains Strong: The EPO Patent Index 2024

The Patent Index 2024, recently published by the European Patent Office (EPO), provides a rich dataset from which key patent trends can be identified. The data shows that demand for …

Read article

A £2.1M Lesson: The Power of Confidential Information

A recent High Court ruling1 serves as a stark reminder of the importance of respecting confidential business information. Hambro Perks, was found guilty of breaching confidentiality and ordered to pay …

Read article

Protecting inventions in Europe and beyond

A patent is  a form of registered intellectual property right granted for new, inventive and industrially applicable inventions. Patents are monopoly rights that  allow their owners (or licensees) the right …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us